1
|
Brown JM, Bentsen MA, Rausch DM, Phan BA, Wieck D, Wasanwala H, Matsen ME, Acharya N, Richardson NE, Zhao X, Zhai P, Secher A, Morton GJ, Pers TH, Schwartz MW, Scarlett JM. Role of hypothalamic MAPK/ERK signaling and central action of FGF1 in diabetes remission. iScience 2021; 24:102944. [PMID: 34430821 PMCID: PMC8368994 DOI: 10.1016/j.isci.2021.102944] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2021] [Revised: 05/28/2021] [Accepted: 07/30/2021] [Indexed: 12/13/2022] Open
Abstract
The capacity of the brain to elicit sustained remission of hyperglycemia in rodent models of type 2 diabetes following intracerebroventricular (icv) injection of fibroblast growth factor 1 (FGF1) is well established. Here, we show that following icv FGF1 injection, hypothalamic signaling by extracellular signal-regulated kinases 1 and 2 (ERK1/2), members of the mitogen-activated protein kinase (MAPK) family, is induced for at least 24 h. Further, we show that this prolonged response is required for the sustained antidiabetic action of FGF1 since it is abolished by sustained (but not acute) pharmacologic blockade of hypothalamic MAPK/ERK signaling. We also demonstrate that FGF1 R50E, a FGF1 mutant that activates FGF receptors but induces only transient hypothalamic MAPK/ERK signaling, fails to mimic the sustained glucose lowering induced by FGF1. These data identify sustained activation of hypothalamic MAPK/ERK signaling as playing an essential role in the mechanism underlying diabetes remission induced by icv FGF1 administration. FGF1 action in the brain induces remission of diabetic hyperglycemia FGF1 induces sustained activation of hypothalamic MAPK/ERK signaling Blockade of hypothalamic MAPK/ERK signaling abolishes the antidiabetic action of FGF1 FGF1 increases hypothalamic astrocyte-neuron interaction by transcriptomic analysis
Collapse
Affiliation(s)
- Jenny M Brown
- Department of Medicine, University of Washington Medicine Diabetes Institute, 750 Republican St, F770, Seattle, WA 98109, USA.,Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, 2200 Copenhagen, Denmark
| | - Marie A Bentsen
- Department of Medicine, University of Washington Medicine Diabetes Institute, 750 Republican St, F770, Seattle, WA 98109, USA.,Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, 2200 Copenhagen, Denmark
| | - Dylan M Rausch
- Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, 2200 Copenhagen, Denmark
| | - Bao Anh Phan
- Department of Medicine, University of Washington Medicine Diabetes Institute, 750 Republican St, F770, Seattle, WA 98109, USA
| | - Danielle Wieck
- Department of Medicine, University of Washington Medicine Diabetes Institute, 750 Republican St, F770, Seattle, WA 98109, USA
| | - Huzaifa Wasanwala
- Department of Medicine, University of Central Florida, Orlando, FL 32827, USA
| | - Miles E Matsen
- Department of Medicine, University of Washington Medicine Diabetes Institute, 750 Republican St, F770, Seattle, WA 98109, USA
| | - Nikhil Acharya
- Department of Medicine, University of Washington Medicine Diabetes Institute, 750 Republican St, F770, Seattle, WA 98109, USA
| | - Nicole E Richardson
- Department of Medicine, University of Washington Medicine Diabetes Institute, 750 Republican St, F770, Seattle, WA 98109, USA
| | - Xin Zhao
- Global Drug Discovery, Novo Nordisk Research China, Beijing 102206, China
| | - Peng Zhai
- Global Drug Discovery, Novo Nordisk Research China, Beijing 102206, China
| | - Anna Secher
- Global Drug Discovery, Novo Nordisk A/S, 2760 Maaloev, Denmark
| | - Gregory J Morton
- Department of Medicine, University of Washington Medicine Diabetes Institute, 750 Republican St, F770, Seattle, WA 98109, USA
| | - Tune H Pers
- Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, 2200 Copenhagen, Denmark
| | - Michael W Schwartz
- Department of Medicine, University of Washington Medicine Diabetes Institute, 750 Republican St, F770, Seattle, WA 98109, USA
| | - Jarrad M Scarlett
- Department of Medicine, University of Washington Medicine Diabetes Institute, 750 Republican St, F770, Seattle, WA 98109, USA.,Department of Pediatric Gastroenterology and Hepatology, Seattle Children's Hospital, Seattle, WA 98145, USA
| |
Collapse
|
2
|
Kohnke S, Buller S, Nuzzaci D, Ridley K, Lam B, Pivonkova H, Bentsen MA, Alonge KM, Zhao C, Tadross J, Holmqvist S, Shimizu T, Hathaway H, Li H, Macklin W, Schwartz MW, Richardson WD, Yeo GSH, Franklin RJM, Karadottir RT, Rowitch DH, Blouet C. Nutritional regulation of oligodendrocyte differentiation regulates perineuronal net remodeling in the median eminence. Cell Rep 2021; 36:109362. [PMID: 34260928 PMCID: PMC8293628 DOI: 10.1016/j.celrep.2021.109362] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2021] [Revised: 04/26/2021] [Accepted: 06/17/2021] [Indexed: 12/13/2022] Open
Abstract
The mediobasal hypothalamus (MBH; arcuate nucleus of the hypothalamus [ARH] and median eminence [ME]) is a key nutrient sensing site for the production of the complex homeostatic feedback responses required for the maintenance of energy balance. Here, we show that refeeding after an overnight fast rapidly triggers proliferation and differentiation of oligodendrocyte progenitors, leading to the production of new oligodendrocytes in the ME specifically. During this nutritional paradigm, ME perineuronal nets (PNNs), emerging regulators of ARH metabolic functions, are rapidly remodeled, and this process requires myelin regulatory factor (Myrf) in oligodendrocyte progenitors. In genetically obese ob/ob mice, nutritional regulations of ME oligodendrocyte differentiation and PNN remodeling are blunted, and enzymatic digestion of local PNN increases food intake and weight gain. We conclude that MBH PNNs are required for the maintenance of energy balance in lean mice and are remodeled in the adult ME by the nutritional control of oligodendrocyte differentiation.
Collapse
Affiliation(s)
- Sara Kohnke
- MRC Metabolic Diseases Unit, University of Cambridge Metabolic Research Laboratories, WT-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, UK
| | - Sophie Buller
- MRC Metabolic Diseases Unit, University of Cambridge Metabolic Research Laboratories, WT-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, UK
| | - Danae Nuzzaci
- MRC Metabolic Diseases Unit, University of Cambridge Metabolic Research Laboratories, WT-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, UK
| | - Katherine Ridley
- Department of Paediatrics and Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK
| | - Brian Lam
- MRC Metabolic Diseases Unit, University of Cambridge Metabolic Research Laboratories, WT-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, UK
| | - Helena Pivonkova
- Wellcome-MRC Cambridge Stem Cell Institute, Department of Veterinary Medicine, University of Cambridge, Cambridge, UK
| | - Marie A Bentsen
- University of Washington Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, WA, USA
| | - Kimberly M Alonge
- University of Washington Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, WA, USA
| | - Chao Zhao
- Wellcome-MRC Cambridge Stem Cell Institute, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
| | - John Tadross
- MRC Metabolic Diseases Unit, University of Cambridge Metabolic Research Laboratories, WT-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, UK
| | - Staffan Holmqvist
- Department of Paediatrics and Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK
| | - Takahiro Shimizu
- Wolfson Institute for Biomedical Research, University College London, London, UK
| | - Hannah Hathaway
- Department of Cell & Developmental Biology and Program in Neuroscience, University of Colorado School of Medicine, Aurora, CO, USA
| | - Huiliang Li
- Wolfson Institute for Biomedical Research, University College London, London, UK
| | - Wendy Macklin
- Department of Cell & Developmental Biology and Program in Neuroscience, University of Colorado School of Medicine, Aurora, CO, USA
| | - Michael W Schwartz
- University of Washington Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, WA, USA
| | - William D Richardson
- Wolfson Institute for Biomedical Research, University College London, London, UK
| | - Giles S H Yeo
- MRC Metabolic Diseases Unit, University of Cambridge Metabolic Research Laboratories, WT-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, UK
| | - Robin J M Franklin
- Wellcome-MRC Cambridge Stem Cell Institute, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
| | - Ragnhildur T Karadottir
- Wellcome-MRC Cambridge Stem Cell Institute, Department of Veterinary Medicine, University of Cambridge, Cambridge, UK
| | - David H Rowitch
- Department of Paediatrics and Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK; Wolfson Institute for Biomedical Research, University College London, London, UK
| | - Clemence Blouet
- MRC Metabolic Diseases Unit, University of Cambridge Metabolic Research Laboratories, WT-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, UK.
| |
Collapse
|
3
|
Alonge KM, Mirzadeh Z, Scarlett JM, Logsdon AF, Brown JM, Cabrales E, Chan CK, Kaiyala KJ, Bentsen MA, Banks WA, Guttman M, Wight TN, Morton GJ, Schwartz MW. Hypothalamic perineuronal net assembly is required for sustained diabetes remission induced by fibroblast growth factor 1 in rats. Nat Metab 2020; 2:1025-1033. [PMID: 32895577 PMCID: PMC7572652 DOI: 10.1038/s42255-020-00275-6] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/08/2020] [Accepted: 08/07/2020] [Indexed: 11/29/2022]
Abstract
We recently showed that perineuronal nets (PNNs) enmesh glucoregulatory neurons in the arcuate nucleus (Arc) of the mediobasal hypothalamus (MBH)1, but whether these PNNs play a role in either the pathogenesis of type 2 diabetes (T2D) or its treatment remains unclear. Here we show that PNN abundance within the Arc is markedly reduced in the Zucker diabetic fatty (ZDF) rat model of T2D, compared with normoglycaemic rats, correlating with altered PNN-associated sulfation patterns of chondroitin sulfate glycosaminoglycans in the MBH. Each of these PNN-associated changes is reversed following a single intracerebroventricular (icv) injection of fibroblast growth factor 1 (FGF1) at a dose that induces sustained diabetes remission in male ZDF rats. Combined with previous work localizing this FGF1 effect to the Arc area2-4, our finding that enzymatic digestion of Arc PNNs markedly shortens the duration of diabetes remission following icv FGF1 injection in these animals identifies these extracellular matrix structures as previously unrecognized participants in the mechanism underlying diabetes remission induced by the central action of FGF1.
Collapse
Affiliation(s)
- Kimberly M Alonge
- University of Washington Medicine Diabetes Institute, University of Washington, Seattle, WA, USA
| | - Zaman Mirzadeh
- Department of Neurosurgery, Barrow Neurological Institute, Phoenix, AZ, USA
| | - Jarrad M Scarlett
- University of Washington Medicine Diabetes Institute, University of Washington, Seattle, WA, USA
- Department of Pediatric Gastroenterology and Hepatology, Seattle Children's Hospital, Seattle, WA, USA
| | - Aric F Logsdon
- Department of Geriatric Research Education and Clinical Center (GRECC), Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, WA, USA
- Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington, Seattle, WA, USA
| | - Jenny M Brown
- University of Washington Medicine Diabetes Institute, University of Washington, Seattle, WA, USA
| | - Elaine Cabrales
- Department of Neurosurgery, Barrow Neurological Institute, Phoenix, AZ, USA
| | - Christina K Chan
- Matrix Biology Program, Benaroya Research Institute, Seattle, WA, USA
| | - Karl J Kaiyala
- Department of Oral Health Sciences, School of Dentistry, University of Washington, Seattle, WA, USA
| | - Marie A Bentsen
- University of Washington Medicine Diabetes Institute, University of Washington, Seattle, WA, USA
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - William A Banks
- Department of Geriatric Research Education and Clinical Center (GRECC), Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, WA, USA
- Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington, Seattle, WA, USA
| | - Miklos Guttman
- Department of Medicinal Chemistry, University of Washington, Seattle, WA, USA
| | - Thomas N Wight
- Matrix Biology Program, Benaroya Research Institute, Seattle, WA, USA
| | - Gregory J Morton
- University of Washington Medicine Diabetes Institute, University of Washington, Seattle, WA, USA
| | - Michael W Schwartz
- University of Washington Medicine Diabetes Institute, University of Washington, Seattle, WA, USA.
| |
Collapse
|
4
|
Bentsen MA, Rausch DM, Mirzadeh Z, Muta K, Scarlett JM, Brown JM, Herranz-Pérez V, Baquero AF, Thompson J, Alonge KM, Faber CL, Kaiyala KJ, Bennett C, Pyke C, Ratner C, Egerod KL, Holst B, Meek TH, Kutlu B, Zhang Y, Sparso T, Grove KL, Morton GJ, Kornum BR, García-Verdugo JM, Secher A, Jorgensen R, Schwartz MW, Pers TH. Transcriptomic analysis links diverse hypothalamic cell types to fibroblast growth factor 1-induced sustained diabetes remission. Nat Commun 2020; 11:4458. [PMID: 32895383 PMCID: PMC7477234 DOI: 10.1038/s41467-020-17720-5] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2020] [Accepted: 07/15/2020] [Indexed: 12/26/2022] Open
Abstract
In rodent models of type 2 diabetes (T2D), sustained remission of hyperglycemia can be induced by a single intracerebroventricular (icv) injection of fibroblast growth factor 1 (FGF1), and the mediobasal hypothalamus (MBH) was recently implicated as the brain area responsible for this effect. To better understand the cellular response to FGF1 in the MBH, we sequenced >79,000 single-cell transcriptomes from the hypothalamus of diabetic Lepob/ob mice obtained on Days 1 and 5 after icv injection of either FGF1 or vehicle. A wide range of transcriptional responses to FGF1 was observed across diverse hypothalamic cell types, with glial cell types responding much more robustly than neurons at both time points. Tanycytes and ependymal cells were the most FGF1-responsive cell type at Day 1, but astrocytes and oligodendrocyte lineage cells subsequently became more responsive. Based on histochemical and ultrastructural evidence of enhanced cell-cell interactions between astrocytes and Agrp neurons (key components of the melanocortin system), we performed a series of studies showing that intact melanocortin signaling is required for the sustained antidiabetic action of FGF1. These data collectively suggest that hypothalamic glial cells are leading targets for the effects of FGF1 and that sustained diabetes remission is dependent on intact melanocortin signaling.
Collapse
MESH Headings
- Agouti-Related Protein/metabolism
- Animals
- Astrocytes/drug effects
- Astrocytes/metabolism
- Blood Glucose/analysis
- Cell Communication
- Cell Nucleus/drug effects
- Cell Nucleus/metabolism
- Diabetes Mellitus, Experimental/blood
- Diabetes Mellitus, Experimental/diet therapy
- Diabetes Mellitus, Experimental/etiology
- Diabetes Mellitus, Experimental/pathology
- Diabetes Mellitus, Type 2/blood
- Diabetes Mellitus, Type 2/drug therapy
- Diabetes Mellitus, Type 2/etiology
- Diabetes Mellitus, Type 2/pathology
- Diet, High-Fat/adverse effects
- Dietary Sucrose/administration & dosage
- Dietary Sucrose/adverse effects
- Fibroblast Growth Factor 1/administration & dosage
- Humans
- Hypoglycemic Agents/administration & dosage
- Hypothalamus/cytology
- Hypothalamus/drug effects
- Hypothalamus/pathology
- Injections, Intraventricular
- Leptin/genetics
- Male
- Melanocortins/metabolism
- Melanocyte-Stimulating Hormones/administration & dosage
- Mice
- Mice, Knockout
- Neurons/drug effects
- Neurons/metabolism
- Oligodendroglia/drug effects
- Oligodendroglia/metabolism
- RNA-Seq
- Receptor, Melanocortin, Type 4/genetics
- Receptors, Melanocortin/antagonists & inhibitors
- Receptors, Melanocortin/metabolism
- Recombinant Proteins/administration & dosage
- Remission Induction/methods
- Signal Transduction/drug effects
- Single-Cell Analysis
- Stereotaxic Techniques
- Transcriptome/drug effects
Collapse
Affiliation(s)
- Marie A Bentsen
- UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Dylan M Rausch
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | | | - Kenjiro Muta
- UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA
- Chakri Naruebodindra Medical Institute, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Jarrad M Scarlett
- UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA
- Department of Pediatric Gastroenterology and Hepatology, Seattle Children's Hospital, Seattle, WA, USA
| | - Jenny M Brown
- UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA
| | - Vicente Herranz-Pérez
- Cavanilles Institute of Biodiversity and Evolutionary Biology, University of Valencia, Valencia, Spain
- Predepartamental Unit of Medicine, Jaume I University, Castelló de la Plana, Spain
| | - Arian F Baquero
- Obesity Research Unit, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA
| | - Jonatan Thompson
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Kimberly M Alonge
- UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA
| | - Chelsea L Faber
- UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA
| | - Karl J Kaiyala
- Department of Oral Health Sciences, School of Dentistry, University of Washington, Seattle, WA, USA
| | - Camdin Bennett
- Obesity Research Unit, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA
| | - Charles Pyke
- Pathology & Imaging, Global Discovery and Development Sciences, Novo Nordisk A/S, Maaloev, Denmark
| | - Cecilia Ratner
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Kristoffer L Egerod
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Birgitte Holst
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Thomas H Meek
- Obesity Research Unit, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA
| | - Burak Kutlu
- Obesity Research Unit, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA
| | - Yu Zhang
- Obesity Research Unit, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA
| | - Thomas Sparso
- Bioinformatics and Data Mining, Global Research Technologies, Novo Nordisk A/S, Maaloev, Denmark
| | - Kevin L Grove
- Obesity Research Unit, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA
| | - Gregory J Morton
- UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA
| | - Birgitte R Kornum
- Department of Neuroscience, University of Copenhagen, Copenhagen, Denmark
| | | | - Anna Secher
- Diabetes Research, Global Drug Discovery, Novo Nordisk A/S, Maaloev, Denmark
| | - Rasmus Jorgensen
- Diabetes Research, Global Drug Discovery, Novo Nordisk A/S, Maaloev, Denmark
- Cytoki Pharma, Copenhagen, Denmark
| | - Michael W Schwartz
- UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA.
| | - Tune H Pers
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
| |
Collapse
|
5
|
Alonge KM, Mirzadeh Z, Scarlett JM, Brown JM, Bentsen MA, Logsdon AF, Banks WA, Guttman M, Wight TN, Morton GJ, Schwartz MW. Assembly of Hypothalamic Perineuronal Nets Contributes to Sustained Blood Glucose Lowering by FGF1 Action in the Brain. FASEB J 2020. [DOI: 10.1096/fasebj.2020.34.s1.05961] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|